Viome Life Sciences
PrivateLast Round
Series D
Sep 10, 2024
Total Funding Raised
$303.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Viome Life Sciences is a biotechnology and healthcare company that utilizes at-home clinical-grade tests and advanced RNA sequencing technology to analyze the human body and its microbiomes, providing personalized health insights and recommendations for chronic disease prevention and reversal.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, D2C Brands, Healthcare Analytics, Subscription Commerce
Business Model
B2C
Customer Profile
Hardware Sales, Hardware + Subscription
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Viome Life Sciences Comparables
Compare Viome Life Sciences with similar companies based on industry and business-model similarity.
Viome Life Sciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Sep 10, 2024 | ||||
| Series C | Aug 18, 2023 | ||||
| Series C | Oct 18, 2022 | ||||
| Convertible Debt | Nov 10, 2021 | ||||
| Series B | Nov 1, 2019 | ||||
VC Round | Jul 6, 2018 |
Viome Life Sciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ocgrow Ventures | Convertible Debt, Series C |
| Ezaki Glico Co., Ltd. | Convertible Debt, Series C |
| Khosla Ventures | Convertible Debt, Series D, Series C, Series A |
| Bold Capital Group | Convertible Debt, Series C |
| WRG Ventures | Series C, Series D |
| WestRiver Group | Convertible Debt, Series C |
| BOLD Capital Partners | Series B, Series A, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 1, 2026
Added Ketch Kloud, Inc. (Technology/Data Privacy) as a customer.
- Jul 14, 2025
Developing an at-home RNA screening test for colon cancer with Scripps.
Recent news
Latest coverage and updates
- hiresAug 16, 2026
Viome Life Sciences, Inc. hired Younggren as president on Aug 16th '26.
- acquiresAug 13, 2026
Viome Life Sciences, Inc. acquired Circulate Health Inc. for $15M on Aug 16th '26.
Viome Life Sciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Viome Life Sciences's valuation, stock price, and market status.
Is Viome Life Sciences a public or private company?
Viome Life Sciences is a private company.
What is the current stock price of Viome Life Sciences?
Viome Life Sciences is a private company with no public stock price. No recent secondary market data is available.
How much is Viome Life Sciences worth (valuation)?
Valuation information for Viome Life Sciences is not publicly available.
Can I buy Viome Life Sciences stock?
Viome Life Sciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Viome Life Sciences's last funding round?
Viome Life Sciences's most recent funding round was Series D on September 10, 2024.
Who are the main investors in Viome Life Sciences?
Key investors in Viome Life Sciences include Khosla Ventures, Bold Capital Group, Bold Capital.
Will Viome Life Sciences IPO soon?
No public IPO plans have been announced for Viome Life Sciences.
How can I track Viome Life Sciences secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Viome Life Sciences's secondary market activity and sign up for updates.